Altech Batteries (ASX:ATC) secures a strategic offtake deal with Axsol GmbH, delivering defence-ready CERENERGY® GridPack batteries with NATO-aligned credentials.
Tryptamine Therapeutics (ASX:TYP) delivers promising interim results from its Phase 2a trial, with 75% of IBS patients reporting reduced abdominal pain and anxiety, marking a significant step for TRP-8803’s clinical pathway.
Lunnon Metals (ASX:LM8) is redefining Kambalda’s geology, confirming gold mineralisation in the overlooked Lunnon Sediment and paving the way for 2025 exploration at Defiance West.
Invex Therapeutics (ASX:IXC) has demonstrated Exenatide’s ability to improve neuronal cell survival by up to 45% in a 3D Alzheimer’s Disease brain model, marking a promising step in neurodegenerative research.
Asian Battery Metals’ latest drilling at North Oval confirms high-grade copper-nickel sulphides, including 3.6m at 3.85% Cu and 3.82% Ni, with further targets lined up for early 2025 exploration.
Encounter Resources uncovers thick, high-grade niobium mineralisation at its Green prospect, signalling transformative potential for WA’s West Arunta region.
Lunnon Metals Lady Herial prospect in Kambalda delivers standout high-grade gold intercepts, showcasing near-surface open-pit potential and exploration upside.
Buxton Resources Graphite Bull project delivers exceptional high-grade results, including 50m at 24.9% TGC, solidifying its position in the booming battery materials market.
Island Pharmaceuticals (ASX: ILA) has secured a U.S. patent for its lead antiviral drug ISLA-101, targeting dengue fever and bolstering its intellectual property portfolio until 2034.
Apollo Minerals (ASX:AON) uncovers shallow high-grade gold at the Salanie Gold Project in Gabon, with results highlighting the untapped potential of this emerging discovery.